Restless legs syndrome

Handbook of Clinical Neurology

Volumn 100, Issue , 2011, Pages 661-673

  Trotti, Lynn marie ^a   Rye, David B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOOK; GENETICS; HUMAN; NERVOUS SYSTEM; PATHOPHYSIOLOGY; RESTLESS LEGS SYNDROME;

HUMANS; NERVOUS SYSTEM; RESTLESS LEGS SYNDROME;

EID: 79954511805     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52014-2.00047-1     Document Type: Book

References (151)

1. Abele M., Burk K., Laccone F., et al. Restless legs syndrome in spinocerebellar ataxia types 1, 2, and 3. J Neurol 2001, 248:311-314.
2. Adler C.H., Hauser R.A., Sethi K., et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004, 62:1405-1407.
3. Aksu M., Bara-Jimenez W. State dependent excitability changes of spinal flexor reflex in patients with restless legs syndrome secondary to chronic renal failure. Sleep Med 2002, 3:427-430.
4. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 2004, 5:385-391.
5. Allen R., Becker P.M., Bogan R., et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004, 27:907-914.
6. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003, 4:101-119.
7. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
8. Allen R.P., Connor J.R., Hyland K., et al. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2008, 10:123-128.
9. Aukerman M.M., Aukerman D., Bayard M., et al. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2006, 19:487-493.
10. Bara-Jimenez W., Aksu M., Graham B., et al. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 2000, 54:1609-1616.
11. Bartell S., Zallek S. Intravenous magnesium sulfate may relieve restless legs syndrome in pregnancy. J Clin Sleep Med 2006, 2:187-188.
12. Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 2006, 7:31-35.
13. Benes H., Heinrich C.R., Ueberall M.A., et al. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004, 27:674-682.
14. Benes H., Walters A.S., Allen R.P., et al. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007, 22:S401-S408.
15. Benes H., von Eye A., Kohnen R. Empirical evaluation of the accuracy of diagnostic criteria for restless legs syndrome. Sleep Med 2008, 10:524-530.
16. Benz R.L., Pressman M.R., Hovick E.T., et al. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000, 35:1052-1060.
17. Berger K., Luedemann J., Trenkwalder C., et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004, 164:196-202.
18. Billars L., Hicks A., Bliwise D., et al. Hypertension risk and PLMS in restless legs syndrome. Sleep 2000, 30:A297-A298.
19. Birinyi P.V., Allen R.P., Hening W., et al. Undiagnosed individuals with first-degree relatives with restless legs syndrome have increased periodic limb movements. Sleep Med 2006, 7:480-485.
20. Bliwise D.L., Freeman A., Ingram C.D., et al. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005, 6:141-147.
21. Bogan R.K., Fry J.M., Schmidt M.H., et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006, 81:17-27.
22. Bucher S.F., Seelos K.C., Oertel W.H., et al. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997, 41:639-645.
23. Castillo P.R., Kaplan J., Lin S.C., et al. Prevalence of restless legs syndrome among native South Americans residing in coastal and mountainous areas. Mayo Clin Proc 2006, 81:1345-1347.
24. Cervenka S., Palhagen S.E., Comley R.A., et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006, 129:2017-2028.
25. Chaudhuri K.R., Rye D.B., Muzerengi S. Differential diagnosis of RLS. Restless Legs Syndrome 2008, 35-43. Oxford University Press, Oxford. K.R. Chaudhuri, L. Ferini-Strambi, D.B. Rye (Eds.).
26. Chen S., Ondo W.G., Rao S., et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 2004, 74:876-885.
27. Chesson A.L., Wise M., Davila D., et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 1999, 22:961-968.
28. Cho Y.W., Shin W.C., Yun C.H., et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008, 31:219-223.
29. Clemens S., Rye D., Hochman S. Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006, 67:125-130.
30. Connor J.R., Boyer P.J., Menzies S.L., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304-309.
31. Cui Y., Wang Y., Liu Z. Acupuncture for restless legs syndrome. Cochrane Database Syst Rev 4: CD006457 2008.
32. Davis B.J., Rajput A., Rajput M.L., et al. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000, 43:70-75.
33. Desai A.V., Cherkas L.F., Spector T.D., et al. Genetic influences in self-reported symptoms of obstructive sleep apnoea and restless legs: a twin study. Twin Res 2004, 7:589-595.
34. Desautels A., Turecki G., Montplaisir J., et al. Analysis of CAG repeat expansions in restless legs syndrome. Sleep 2003, 26:1055-1057.
35. d'Onofrio F., Bussone G., Cologno D., et al. Restless legs syndrome and primary headaches: a clinical study. Neurol Sci 2008, 29:S169-S172.
36. Driver-Dunckley E.D., Noble B.N., Hentz J.G., et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007, 30:249-255.
37. Earley C.J., Allen R.P. Restless legs syndrome augmentation associated with tramadol. Sleep Med 2006, 7:592-593.
38. Earley C.J., Allen R.P., Beard J.L., et al. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000, 62:623-628.
39. Earley C.J., Heckler D., Allen R.P. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004, 5:231-235.
40. Earley C.J., Hyland K., Allen R.P. Circadian changes in CSF dopaminergic measures in restless legs syndrome. Sleep Med 2006, 7:263-268.
41. Earley C.J., Horska A., Mohamed M.A., et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2008, 10:206-211.
42. Ferini-Strambi L., Aarskog D., Partinen M., et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Med 2008, 9:874-881.
43. Garcia-Borreguero D., Larrosa O., de la Llave Y., et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002, 59:1573-1579.
44. Garcia-Borreguero D., Allen R.P., Kohnen R., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007, 8:520-530.
45. Garcia-Borreguero D., Kohnen R., Hogl B., et al. Validation of the Augmentation Severity Rating Scale (ASRS). Sleep Med 2007, 8:455-463.
46. Garcia-Borreguero D., Allen R.P., Benes H., et al. Augmentation as a treatment complication of restless legs syndrome: concept and management. Mov Disord 2007, 22:S476-S484.
47. Gemignani F., Marbini A., Di Giovanni G., et al. Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology 1999, 52:1064-1066.
48. Godau J., Wevers A.K., Gaenslen A., et al. Sonographic abnormalities of brainstem structures in restless legs syndrome. Sleep Med 2008, 9:782-789.
49. Godau J., Klose U., Di Santo A., et al. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord 2008, 23:1184-1187.
50. Gomez-Esteban J.C., Zarranz J.J., Tijero B., et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2007, 22:1912-1916.
51. Happe S., Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004, 18:27-36.
52. Happe S., Vennemann M., Evers S., et al. Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol 2008, 255:1365-1371.
53. Hayes C.A., Kingsley J.R., Hamby K.R., et al. The effect of endovenous laser ablation on restless legs syndrome. Phlebology 2008, 23:112-117.
54. Hening W.A. Current guidelines and standards of practice for restless legs syndrome. Am J Med 2007, 120:S22-S27.
55. Hening W.A., Caivano C.K. Restless legs syndrome: A common disorder in patients with rheumatologic conditions. Semin Arthritis Rheum 2008, 38:55-62.
56. Hening W., Walters A.S., Allen R.P., et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004, 5:237-246.
57. Hornyak M., Voderholzer U., Riemann D. Treatment of depression in patients with restless legs syndrome: what is evidence-based?. Sleep Med 2006, 7:303-304.
58. Jakobsson B., Ruuth K. Successful treatment of restless legs syndrome with an implanted pump for intrathecal drug delivery. Acta Anaesthesiol Scand 2002, 46:114-117.
59. Kavanagh D., Siddiqui S., Geddes C.C. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004, 43:763-771.
60. Kemlink D., Plazzi G., Vetrugno R., et al. Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics 2008, 9:75-82.
61. Konieczny M., Bauer P., Tomiuk J., et al. CAG repeats in restless legs syndrome. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:173-176.
62. Kushida C.A., Walters A.S., Becker P., et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009, 32:159-168.
63. Kushida C.A., Becker P.M., Ellenbogen A.L., et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009, 72:439-446.
64. Kushida C., Martin M., Nikam P., et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007, 16:617-624.
65. Lavigne G.J., Montplaisir J.Y. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep 1994, 17:739-743.
66. Lee H.B., Hening W.A., Allen R.P., et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci 2008, 20:101-105.
67. Lee S.J., Kim J.S., Song I.U., et al. Poststroke restless legs syndrome and lesion location: anatomical considerations. Mov Disord 2008, 24:77-84.
68. Lettieri C.J., Eliasson A.H. Pneumatic compression devices are an effective therapy for restless legs syndrome. Chest 2008, 135:74-80.
69. Lindvall P., Ruuth K., Jakobsson B., et al. Intrathecal morphine as a treatment for refractory restless legs syndrome. Neurosurgery 2008, 63:E1209.
70. Lo Coco D., Mattaliano A., Coco A.L., et al. Increased frequency of restless legs syndrome in chronic obstructive pulmonary disease patients. Sleep Med 2008, 10:572-576.
71. Lohmann-Hedrich K., Neumann A., Kleensang A., et al. Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci?. Neurology 2008, 70:686-694.
72. Manconi M., Govoni V., De Vito A., et al. Restless legs syndrome and pregnancy. Neurology 2004, 63:1065-1069.
73. Manconi M., Fabbrini M., Bonanni E., et al. High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007, 14:534-539.
74. Merlino G., Fratticci L., Valente M., et al. Association of restless legs syndrome in type 2 diabetes: A case-control study. Sleep 2007, 30:866-871.
75. Michaud M., Soucy J.P., Chabli A., et al. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002, 249:164-170.
76. Minai O.A., Malik N., Foldvary N., et al. Prevalence and characteristics of restless legs syndrome in patients with pulmonary hypertension. J. Heart Lung Transplant. 2008, 27:335-340.
77. Miranda M., Kagi M., Fabres L., et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004, 62:831-832.
78. Molnar M.Z., Novak M., Ambrus C., et al. Restless legs syndrome in patients after renal transplantation. Am J Kidney Dis 2005, 45:388-396.
79. Montplaisir J., Nicolas A., Denesle R., et al. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999, 52:938-943.
80. Montplaisir J., Denesle R., Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000, 7:27-31.
81. Morgan J.C., Ames M., Sethi K.D. Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin. J Neurol Neurosurg Psychiatry 2008, 79:964-965.
82. Nahab F.B., Peckham E.L., Hallett M. Double-blind, placebo-controlled, pilot trial of botulinum toxin A in restless legs syndrome. Neurology 2008, 71:950-951.
83. Nardone R., Ausserer H., Bratti A., et al. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurol Scand 2006, 114:244-249.
84. Nelson C., Erikson K., Pinero D.J., et al. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 1997, 127:2282-2288.
85. Nichols D.A., Allen R.P., Grauke J.H., et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003, 163:2323-2329.
86. Nomura T., Inoue Y., Kusumi M., et al. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord 2008, 23:2363-2369.
87. Nordlander N.B. Therapy in restless legs. Acta Med Scand 1953, 145:453-457.
88. Oertel W.H., Benes H., Bodenschatz R., et al. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). Neurology 2006, 67:1040-1046.
89. Oertel W.H., Benes H., Garcia-Borreguero D., et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008, 9:865-873.
90. O'Keeffe S.T., Gavin K., Lavan J.N. Iron status and restless legs syndrome in the elderly. Age Ageing 1994, 23:200-203.
91. O'Keeffe S.T., Egan D., Myers A., et al. The frequency and impact of restless legs syndrome in primary care. Ir Med J 2007, 100:539-542.
92. Ondo W.G., Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008, 14:28-32.
93. Ondo W.G., Vuong K.D., Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000, 55:1404-1406.
94. Partinen M., Hirvonen K., Jama L., et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study - the PRELUDE study. Sleep Med 2006, 7:407-417.
95. Paulus W., Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006, 5:878-886.
96. Phillips B., Young T., Finn L., et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000, 160:2137-2141.
97. Picchietti D., Allen R.P., Walters A.S., et al. Restless legs syndrome: prevalence and impact in children and adolescents - the Peds REST study. Pediatrics 2007, 120:253-266.
98. Picchietti D.L., Stevens H.E. Early manifestations of restless legs syndrome in childhood and adolescence. Sleep Med 2008, 9:770-781.
99. Poceta J.S., Parsons L., Engelland S., et al. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med 2009, 10:129-133.
100. Quickfall J., Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007, 13:535-536.
101. Qu S., Le W., Zhang X., et al. Locomotion is increased in 11-lesioned mice with iron deprivation: a possible animal model for restless legs syndrome. J Neuropathol Exp Neurol 2007, 66:383-388.
102. Ross D.A., Narus M.S., Nutt J.G. Control of medically refractory restless legs syndrome with intrathecal morphine: case report. Neurosurgery 2008, 62:E263. discussion E263.
103. Rotenberg J.S., Canard K., Difazio M. Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. J Clin Sleep Med 2006, 2:275-278.
104. Rottach K.G., Schaner B.M., Kirch M.H., et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008, 43:70-75.
105. Ruottinen H.M., Partinen M., Hublin C., et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000, 54:502-504.
106. San Pedro E.C., Mountz J.M., Mountz J.D., et al. Familial painful restless legs syndrome correlates with pain dependent variation of blood flow to the caudate, thalamus, and anterior cingulate gyrus. J Rheumatol 1998, 25:2270-2275.
107. Scalise A., Cadore I.P., Gigli G.L. Motor cortex excitability in restless legs syndrome. Sleep Med 2004, 5:393-396.
108. Schmidauer C., Sojer M., Seppi K., et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 2005, 58:630-634.
109. Schormair B., Kemlink D., Roeske D., et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 2008, 40:946-948.
110. Sevim S., Dogu O., Camdeviren H., et al. Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 2003, 61:1562-1569.
111. Silber M.H., Ehrenberg B.L., Allen R.P., et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004, 79:916-922.
112. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004, 76:74-78.
113. Sloand J.A., Shelly M.A., Feigin A., et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663-670.
114. Sommer M., Bachmann C.G., Liebetanz K.M., et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007, 115:347-350.
115. Stefansson H., Rye D.B., Hicks A., et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007, 357:639-647.
116. Stiasny-Kolster K., Moller J.C., Zschocke J., et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord 2004, 19:192-196.
117. Stiasny-Kolster K., Kohnen R., Schollmayer E., et al. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004, 19:1432-1438.
118. Stiasny-Kolster K., Kohnen R., Moller J.C., et al. Validation of the " 0L-DOPA test" for diagnosis of restless legs syndrome. Mov Disord 2006, 21:1333-1339.
119. Tan E.K., Seah A., See S.J., et al. Restless legs syndrome in an Asian population: A study in Singapore. Mov Disord 2001, 16:577-579.
120. Tippmann-Peikert M., Park J.G., Boeve B.F., et al. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68:301-303.
121. Trenkwalder C., Walters A.S., Hening W.A., et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999, 14:141-145.
122. Trenkwalder C., Garcia-Borreguero D., Montagna P., et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004, 75:92-97.
123. Trenkwalder C., Benes H., Grote L., et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov Disord 2007, 22:696-703.
124. Trenkwalder C., Hening W.A., Montagna P., et al. Treatment of restless legs syndrome 2008, An evidence-based review and implications for clinical practice. Mov Disord 23: 2267-2302.
125. Trenkwalder C., Hogl B., Benes H., et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008, 9:572-574.
126. Tribl G.G., Asenbaum S., Klosch G., et al. Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2002, 59:649-650.
127. Trotti L.M., Rye D.B. Functional anatomy and treatment of RLS/PLMS emerging after spinal cord lesions. Sleep 2007, 30:A306.
128. Trotti L.M., Bhadriraju S., Rye D.B. An update on the pathophysiology and genetics of restless legs syndrome. Curr Neurol Neurosci Rep 2008, 8:281-287.
129. Trotti L.M., Bliwise D.L., Greer S.A., et al. Correlates of plms variability over multiple nights and impact upon RLS diagnosis. Sleep Med 2009, 10:668-671.
130. Turjanski N., Lees A.J., Brooks D.J. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999, 52:932-937.
131. Ulfberg J., Nystrom B., Carter N., et al. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord 2001, 16:1159-1163.
132. Ulfberg J., Bjorvatn B., Leissner L., et al. Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 2007, 8:768-772.
133. Umbreit J. Iron deficiency: a concise review. Am J Hematol 2005, 78:225-231.
134. Unger E.L., Earley C.J., Beard J.L., et al. Diurnal cycle influences peripheral and brain iron levels in mice. J Appl Physiol 2009, 106:187-193.
135. Unrath A., Muller H.P., Ludolph A.C., et al. Cerebral white matter alterations in idiopathic restless legs syndrome, as measured by diffusion tensor imaging. Mov Disord 2008, 23:1250-1255.
136. Urbano M.R., Ware J.C. Restless legs syndrome caused by quetiapine successfully treated with ropinirole in 2 patients with bipolar disorder. J Clin Pharmacol 2008, 28:704-705.
137. Vilarino-Guell C., Farrer M.J., Lin S.C. A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2008, 358:425-427.
138. Wagner M.L., Walters A.S., Coleman R.G., et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996, 19:52-58.
139. Walters A.S., Winkelmann J., Trenkwalder C., et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001, 16:1105-1109.
140. Walters A.S., Ondo W.G., Dreykluft T., et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004, 19:1414-1423.
141. Wang J., O'Reilly B., Venkataraman R., et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009, 10:973-975.
142. Winkelmann J., Stautner A., Samtleben W., et al. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Mov Disord 2002, 17:1072-1076.
143. Winkelmann J., Polo O., Provini F., et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord 2007, 22:S449-S458.
144. Winkelmann J., Schormair B., Lichtner P., et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 2007, 39:1000-1006.
145. Winkelmann J., Lichtner P., Schormair B., et al. Variants in the neuronal nitric oxide synthase (nnos, NOS1) gene are associated with restless legs syndrome. Mov Disord 2008, 23:350-358.
146. Winkelman J.W. Periodic limb movements in sleep - endophenotype for restless legs syndrome?. N Engl J Med 2007, 357:703-705.
147. Winkelman J.W., Chertow G.M., Lazarus J.M. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996, 28:372-378.
148. Winkelman J.W., Sethi K.D., Kushida C.A., et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006, 67:1034-1039.
149. Winkelman J.W., Finn L., Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006, 7:545-552.
150. Winkelman J.W., Shahar E., Sharief I., et al. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008, 70:35-42.
151. Zanettini R., Antonini A., Gatto G., et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46.